zidesamtinib

News

New trial data sets up a filing for Nuvalent's new-generation ROS1 inhibitor in NSCLC, although it has an uphill battle to catch rival Nuvation.

News

Novo Nordisk has claimed a key win in its head-to-head race with Agios to bring an oral PKR activator to the market for sickle cell disease.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.